Literature DB >> 16760579

Expression of MAGE tumor-associated antigen in thyroid carcinomas.

Marija Milkovic1, Bozena Sarcevic, Elizabet Glavan.   

Abstract

The 12 members of the MAGE gene family encode tumor-specific antigens that are recognized by autologous cytotoxic T lymphocytes. The MAGE genes are expressed not only in melanoma but in other malignant tumors as well. There is, however, little information on their expression in thyroid carcinomas. We studied the expression of the MAGE-3 antigen in human thyroid carcinomas to explore the possibility of specific immunotherapy using MAGE peptides. Tumor tissue samples of thyroid carcinomas were obtained from 60 patients. Standard pathohistologic analysis followed by immunohistochemistry analysis of MAGE-3 expression was performed in all patients. The overall expression rate of MAGE-3 antigen in thyroid carcinomas was 65%. According to histological types of thyroid carcinomas, expression rate of MAGE-3 antigen was as follows: 0% in anaplastic, 20% in medullary, 29% in follicular, and 80% in papillary thyroid carcinomas (p < 0.01). On the other hand, significantly higher expression of MAGE-3 antigen was observed in classical subtypes of papillary thyroid carcinomas and in small papillary tumors sized to 1 cm in diameter. These findings demonstrated that MAGE-3 antigen expression seems to be particularly high in the small, typical papillary carcinomas, thus suggesting that MAGE-3 gene abnormality is an early step in thyroid cancer progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760579     DOI: 10.1385/ep:17:1:45

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  36 in total

Review 1.  The role of apoptosis in autoimmune thyroid disorders and thyroid cancer.

Authors:  J D Lin
Journal:  BMJ       Date:  2001-06-23

2.  Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.

Authors:  T Nishiyama; M Tachibana; Y Horiguchi; K Nakamura; Y Ikeda; K Takesako; M Murai
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

3.  Functional characterization of T lymphocytes propagated from human lung carcinomas.

Authors:  J T Kurnick; R L Kradin; R Blumberg; E E Schneeberger; L A Boyle
Journal:  Clin Immunol Immunopathol       Date:  1986-03

4.  Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data.

Authors:  S Schröder; W Schwarz; W Rehpenning; T Löning; W Böcker
Journal:  Am J Clin Pathol       Date:  1988-03       Impact factor: 2.493

5.  MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.

Authors:  G F Hofbauer; C Schaefer; C Noppen; R Böni; J Kamarashev; F O Nestle; G C Spagnoli; R Dummer
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

6.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

7.  Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes.

Authors:  H Inoue; M Mori; J Li; K Mimori; M Honda; H Nakashima; K Mafune; Y Tanaka; T Akiyoshi
Journal:  Int J Cancer       Date:  1995-11-15       Impact factor: 7.396

8.  Expression of MAGE genes in primary and metastatic cutaneous melanoma.

Authors:  F Brasseur; D Rimoldi; D Liénard; B Lethé; S Carrel; F Arienti; L Suter; R Vanwijck; A Bourlond; Y Humblet
Journal:  Int J Cancer       Date:  1995-11-03       Impact factor: 7.396

9.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

10.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

View more
  6 in total

1.  A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Authors:  Viswanath Gunda; Dennie T Frederick; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Thyroid       Date:  2014-06-30       Impact factor: 6.568

2.  Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Authors:  Viswanath Gunda; Alexandria P Cogdill; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

3.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

4.  CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Authors:  Mariana Bonjiorno Martins; Marjory Alana Marcello; Fernando de Assis Batista; Lucas Leite Cunha; Elaine Cristina Morari; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  J Immunol Res       Date:  2014-11-04       Impact factor: 4.818

5.  Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.

Authors:  Daniel Hardy Melo; Rui Celso Martins Mamede; Luciano Neder; Wilson Araújo Silva; Mateus Camargo Barros-Filho; Luiz Paulo Kowalski; Clóvis Antonio Lopes Pinto; Marco Antônio Zago; David Livingstone Alves Figueiredo; Achim A Jungbluth
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 6.  Novel targeted therapies and immunotherapy for advanced thyroid cancers.

Authors:  George E Naoum; Michael Morkos; Brian Kim; Waleed Arafat
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.